Author

Allison Barz Leahy

Children's Hospital of PhiladelphiaORCID 0000-0002-1368-4064Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Ash A. AlizadehiD· 1 shared Astraea Jager· 1 shared Bita SahafiD· 1 shared Bonnie YatesiD· 1 shared Brian J. SworderiD· 1 shared Charles Grenfell MullighaniD· 1 shared Crystal Lee MackalliD· 1 shared David M. BarrettiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ash A. AlizadehORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia

Pablo Domizi, Jolanda Sarno, Astraea Jager, Milton J. Merchant, Kaithlen Zen Pacheco, Sean A. Yamada‐Hunter, Maria Caterina Rotiroti, Yuxuan Liu, Reema Baskar, Warren D. Reynolds, Brian J. Sworder, Bita Sahaf, Sean C. Bendall, Charles Grenfell Mullighan, Ash A. Alizadeh, , Kara Lynn Davis

This study identifies IKAROS as a factor associated with antigen escape in B-ALL, showing that low IKAROS levels lead to reduced B-cell antigen expression and resistance to CD19- and CD22-targeted therapies.

Nature Communications · Apr 23, 2025Peer-reviewedCancer Biology